Hi-Risk/Recurrent/Advanced PrCa Video Chat, Nov 2, 2026

by | Nov 3, 2026 | High Risk/Recurrent/Advanced, High Risk/Recurrent/Advanced Prostate Cancer, mCRPC, mHSPC, Prostate Cancer, Recorded Groups, Uncategorized

Intermediate Risk Prostate Cancer Graphic

Hi-Risk/Recurrent/Advanced PrCa Video Chat, Nov 2, 2026

AnCan IS ON SUBSTACK… find us at https://ancanspeak.substack.com/. Please sign up. We’re posting the best of all our Reminders.

AnCan thanks the following sponsors for making this recording possible: Novartis, Telix and Blue Earth Diagnostics.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.

AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.

AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download

All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/

Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room

Editor’s Pick:  Does the PROTEUS trial (RRP + doublet) set a good example?

Topics Discussed

Does surgery with doublet (PROTEUS trial) make sense for 72 yr old; Dana Farber visit raises questions about ‘diffuse’ cells and PSMA tracer agents; sensitive PSA test needed post surgery; VA approves daro but too early for Truqap; hormone resistance post triplet raises RLT vs chemo vs ???; Cu67 SAR-bisPSMA alternative to Pluvicto; switch to local GU PSMA for ease of treatment; small peritoneal lesions double in size to 4mm over 5 years – treat or not?; drug holiday success – PSA declines and T rises 🎉

Chat